Claims

1 Stable pharmaceutical compositions of 5,10-methylene-(6R)-, -(6S)-or -(6R,S)-tetrahydrofolate, characterised in that the composition comprises 5,10-methylene-(6R)-, -(6S)- or -(6R,S)-tetrahydrofolic acid or a pharmaceutically acceptable salt of 5,10-methylene-(6R)-, -(6S)- or -(6R,S)-tetrahydrofolic acid together with citrate, and has a pH between 7.5 and 10.5, preferably between 8.5 and 9.5.

2 Stable pharmaceutical compositions according to claim 1 together with further pharmaceutically acceptable active ingredients and adjuvants.

3 A pharmaceutical composition according to claim 2, characterised in that it comprises formaldehyde as an adjuvant.

4 A pharmaceutical composition according to claim 2, characterised in that it comprises a further folate as a further active ingredient.

5 A pharmaceutical composition according to claim 4, characterised in that it comprises tetrahydrofolic acid and salts thereof as a further folate.

6 A pharmaceutical composition according to claim 1, characterised in that the calcium salt or an acidic salt is used as the pharmaceutically acceptable salt of 5,10-methylene-(6R)-, -(6S)- or -(6R,S)-tetrahydrofolic acid.

7 A pharmaceutical composition according to claim 2, characterised in that it comprises a cytostatic agent as a further active ingredient .

8 A pharmaceutical composition according to claim 2, characterised in that it comprises a fluorinated pyrimidine derivative as a further active ingredient.

9 A pharmaceutical composition according to claim 8, characterised in that it comprises 5-fluoruracil or a 5-fluoruracil prodrug, particularly capecitabine (xeloda) as a fluorinated pyrimidine derivative.

10 A pharmaceutical composition according to any one of claims 1 to 9, additionally comprising at least one antioxidant or a radical scavenger.

11 A pharmaceutical composition according to claim 10, characterised in that it comprises vitamin C or reduced glutathione as an antioxidant or radical scavenger.

12 A pharmaceutical composition according to any one of claims 1 to 11, characterised in that the composition exists as a lyophilisate, dry powder or dry mixture.

13 A pharmaceutical composition according to any one of claims 1 to 11, characterised in that the composition exists as a lyophilisation solution.

14 A method of stabilising compositions comprising 5,10-methylene-(6R)-, -(6S)- or -(6R,S)-tetrahydrofolate, characterised in that 5,10-methylene-(6R)-, -(6S)- or -(6R,S)-tetrahydrofolic acid is treated with citrate and is brought to a pH between 7.5 and 10.5, preferably between 8.5 and 9.5.

15 Use of compositions comprising a pharmaceutically acceptable salt of 5,10-methylene-(6R)-, -(6S)- or -(6R,S)-tetrahydrofolic acid and citrate at a pH between 7.5 and 10.5, preferably between 8.5 and 9.5, for producing a pharmaceutical preparation suitable for use for corresponding medical indications.